320 related articles for article (PubMed ID: 18304395)
21. Annual disease burden due to human papillomavirus (HPV) 6 and 11 infections in Finland.
Syrjänen KJ
Scand J Infect Dis Suppl; 2009; 107():3-32. PubMed ID: 19408160
[TBL] [Abstract][Full Text] [Related]
22. [HPV vaccination: principles, results and future perspectives].
Rouzier R; Uzan C; Collinet P
J Gynecol Obstet Biol Reprod (Paris); 2007 Feb; 36(1):13-8. PubMed ID: 17293248
[TBL] [Abstract][Full Text] [Related]
23. [Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].
Bégué P; Henrion R; Blanc B; Girard M; Sancho-Garnier H
Bull Acad Natl Med; 2007 Dec; 191(9):1805-16; discussion 1816-7. PubMed ID: 18663976
[TBL] [Abstract][Full Text] [Related]
24. From the monovalent to the nine-valent HPV vaccine.
Pils S; Joura EA
Clin Microbiol Infect; 2015 Sep; 21(9):827-33. PubMed ID: 25980355
[TBL] [Abstract][Full Text] [Related]
25. Cervical cancer prevention in the human papilloma virus vaccine era.
Ghazal-Aswad S
Ann N Y Acad Sci; 2008 Sep; 1138():253-6. PubMed ID: 18837904
[TBL] [Abstract][Full Text] [Related]
26. Prophylactic HPV vaccines: new interventions for cancer control.
Barr E; Sings HL
Vaccine; 2008 Nov; 26(49):6244-57. PubMed ID: 18694795
[TBL] [Abstract][Full Text] [Related]
27. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
[TBL] [Abstract][Full Text] [Related]
28. Human papillomavirus vaccines and anal carcinoma.
Franceschi S; De Vuyst H
Curr Opin HIV AIDS; 2009 Jan; 4(1):57-63. PubMed ID: 19339940
[TBL] [Abstract][Full Text] [Related]
29. STD-prevention counseling practices and human papillomavirus opinions among clinicians with adolescent patients--United States, 2004.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2006 Oct; 55(41):1118-20. PubMed ID: 17060897
[TBL] [Abstract][Full Text] [Related]
30. Human papillomavirus anogenital disease in HIV-infected individuals.
Chin-Hong PV; Palefsky JM
Dermatol Ther; 2005; 18(1):67-76. PubMed ID: 15842614
[TBL] [Abstract][Full Text] [Related]
31. HPV vaccination - a paradigm shift in public health.
May J
Aust Fam Physician; 2007 Mar; 36(3):106-11. PubMed ID: 17339969
[TBL] [Abstract][Full Text] [Related]
32. Epidemiology of mucosal human papillomavirus infection and associated diseases.
Trottier H; Burchell AN
Public Health Genomics; 2009; 12(5-6):291-307. PubMed ID: 19684442
[TBL] [Abstract][Full Text] [Related]
33. Prevention of human papillomavirus infections and associated diseases by vaccination: a new hope for global public health.
Harper DM
Public Health Genomics; 2009; 12(5-6):319-30. PubMed ID: 19684444
[TBL] [Abstract][Full Text] [Related]
34. Epidemiology of anogenital warts and cancer.
Franco EL
Obstet Gynecol Clin North Am; 1996 Sep; 23(3):597-623. PubMed ID: 8869948
[TBL] [Abstract][Full Text] [Related]
35. An overview of human papillomavirus infection for the dermatologist: disease, diagnosis, management, and prevention.
Forcier M; Musacchio N
Dermatol Ther; 2010; 23(5):458-76. PubMed ID: 20868401
[TBL] [Abstract][Full Text] [Related]
36. Vaccination against human papillomavirus.
BMJ Group
Drug Ther Bull; 2008 Dec; 46(12):89-93. PubMed ID: 19056700
[TBL] [Abstract][Full Text] [Related]
37. Human papillomavirus and cervical cancer: burden of illness and basis for prevention.
Trottier H; Franco EL
Am J Manag Care; 2006 Dec; 12(17 Suppl):S462-72. PubMed ID: 17203990
[TBL] [Abstract][Full Text] [Related]
38. Short version of the German evidence-based Guidelines for prophylactic vaccination against HPV-associated neoplasia.
Pathirana D; Hillemanns P; Petry KU; Becker N; Brockmeyer NH; Erdmann R; Gissmann L; Grundhewer H; Ikenberg H; Kaufmann AM; Klusmann J; Kopp I; Pfister H; Rzany B; Schneede P; Schneider A; Smola S; Winter-Koch N; Wutzler P; Gross G
Vaccine; 2009 Jul; 27(34):4551-9. PubMed ID: 19524337
[TBL] [Abstract][Full Text] [Related]
39. The new human papillomavirus (HPV) vaccine: pros and cons for pediatric and adolescent health.
Thomas TL
Pediatr Nurs; 2008; 34(5):429-31. PubMed ID: 19051848
[TBL] [Abstract][Full Text] [Related]
40. Prophylactic HPV vaccination for women over 18 years of age.
Adams M; Jasani B; Fiander A
Vaccine; 2009 May; 27(25-26):3391-4. PubMed ID: 19200838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
